欢迎关注凯莱英药闻近期，诺和诺德在基因编辑领域进一步加码；首先是在2024年6月，公司以最高4000万美元收购2seventy bio的A ...

On Friday, 2Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $4.93 which represents a slight increase of $0.17 or 3.57% from the prior close of $4.76. The stock opened at $4.83 and ...

据了解，2seventy ...

Daina Graybosch, an analyst from Leerink Partners, reiterated the Buy rating on 2seventy bio (TSVT – Research Report). The associated ...

Inc. (Nasdaq: TSVT) today announced that the Company, in partnership with study sponsor Bristol Myers Squibb (BMS), will ...

CAMBRIDGE, Mass. - 2seventy bio, Inc. (NASDAQ:TSVT)和百时美施贵宝公司(NYSE:BMY)联合宣布停止招募KarMMa-9三期研究。该研究旨在评估Abecma联合来那度胺维持治疗对自体干细胞移植后反应不佳的新诊断多发性骨髓瘤(NDMM)患者的疗效。 这一决定预计将在未来几年为2seventy bio节省超过8000万美元，并加速公司在2025年实现 ...

据了解，2seventy bio和其合作伙伴百时美施贵宝宣布，将停止新诊断的多发性骨髓瘤患者使用的T细胞免疫疗法Abecma的III期临床试验。这项名为KarMMa-9的研究，旨在评估Abecma与来那度胺联合治疗，以及来那度胺单药治疗的效果。两家公司表示，这一决定是在对该研究的商业理由进行彻底审查后做出的。

（原标题：2seventy bio(TSVT.US)与百时美施贵宝(BMY.US)停止多发性骨髓瘤疗法试验 预计节省8000万美元） 智通财经APP获悉，2seventy ...

Inc (NASDAQ:TSVT) and its partner Bristol Myers Squibb & Co (NYSE:BMY), will discontinue enrollment in its ongoing Phase 3 ...

US biotech 2seventy bio and partner Bristol Myers Squibb today revealed that they will discontinue enrollment in its ongoing ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on 2seventy bio (TSVT – Research Report), with a ...

(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...